IMMUCELL CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IMMUCELL CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.49M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $17.47M | Mar 28, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.64M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $26.49M | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | $17.47M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $18.57M | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.45M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.94M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.87M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $7.65M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.66M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $6.86M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.74M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.19M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.22M | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | $1.22M | Mar 30, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.04M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.16M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($5.77M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.49M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($78.3K) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($1.02M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.30M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.32M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($168.1K) | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | $30.3K | Mar 30, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.64M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($5.75M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.30M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $257.4K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($1.38M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($953.9K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.45M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($242.8K) | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | $119.3K | Mar 30, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.90M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.39M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.17M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.69M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.52M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.05M | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | $253.7K | Mar 30, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.48M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $357.9K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.67M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($1.54M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $954.2K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.32M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $233.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($373.4K) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.18M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($222.3K) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $465.7K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.89M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.98M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.61M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.07M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.39M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.03M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $17.76M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $3.59M | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $45.10M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $43.81M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $44.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $44.47M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $40.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $38.69M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $32.73M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $34.30M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $24.70M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.48M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $17.58M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $18.82M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $14.48M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.89M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $12.08M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $9.70M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $10.99M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $10.70M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $4.98M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.06M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $27.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $24.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $30.38M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $32.58M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $28.27M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $28.99M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $21.74M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $23.59M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $19.72M | Mar 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.6K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $95.6K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $95.6K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $95.6K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $95.6K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $95.6K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $95.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $95.6K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $95.6K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $95.6K | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.16M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($12.01M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($6.23M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.74M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($3.66M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.64M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.34M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $979.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.15M | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.76M | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | $978.7K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $5.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.19M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $6.95M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.29M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.52M | Mar 27, 2020 |
| FY2019 | Dec 31, 2017 | $3.80M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $5.15M | Mar 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.10M | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | $10.23M | Mar 29, 2023 |
| FY2021 | Dec 31, 2021 | $812.2K | Mar 30, 2022 |
| FY2020 | Dec 31, 2020 | $9.50M | Mar 30, 2021 |
| FY2019 | Dec 31, 2019 | $8.42M | Mar 27, 2020 |
| FY2018 | Dec 31, 2018 | $9.27M | Mar 22, 2019 |
| FY2017 | Dec 31, 2017 | $8.96M | Mar 29, 2018 |
| FY2013 | Dec 31, 2013 | $929.2K | Mar 26, 2014 |
| FY2013 | Dec 31, 2012 | $1.17M | Mar 26, 2014 |
| FY2012 | Dec 31, 2011 | $1.34M | Mar 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 30, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 30, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.05M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 8.98M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 7.75M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 7.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 7.74M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 7.22M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 7.21M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 5.57M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 5.48M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 4.85M | Mar 29, 2018 |